Compare MRVI & VBNK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MRVI | VBNK |
|---|---|---|
| Founded | 2014 | 1980 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Commercial Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 472.8M | 499.0M |
| IPO Year | 2020 | 2021 |
| Metric | MRVI | VBNK |
|---|---|---|
| Price | $2.93 | $16.62 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 2 |
| Target Price | $4.57 | ★ $13.00 |
| AVG Volume (30 Days) | ★ 1.1M | 42.3K |
| Earning Date | 02-25-2026 | 03-04-2026 |
| Dividend Yield | N/A | ★ 0.45% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.64 |
| Revenue | ★ $192,435,000.00 | $85,792,576.00 |
| Revenue This Year | N/A | $37.01 |
| Revenue Next Year | $10.00 | $30.71 |
| P/E Ratio | ★ N/A | $25.63 |
| Revenue Growth | N/A | ★ 7.44 |
| 52 Week Low | $1.67 | $8.51 |
| 52 Week High | $4.40 | $16.99 |
| Indicator | MRVI | VBNK |
|---|---|---|
| Relative Strength Index (RSI) | 30.37 | 64.32 |
| Support Level | $2.92 | $15.88 |
| Resistance Level | $3.17 | $16.99 |
| Average True Range (ATR) | 0.18 | 0.41 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 4.52 | 75.95 |
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
VersaBank is a Schedule I Canadian bank that provides mainly commercial lending and banking services to select niche markets in Canada and the United States. Its products and services include credit assets, deposits, and cybersecurity services through its wholly owned subsidiary. The bank operates through four segments: Digital Banking Canada and Digital Banking USA, both using a business-to-business model with proprietary financial technology to serve underserved markets; DRTC, which provides cybersecurity services and banking and financial technology development; and Digital Meteor, which owns proprietary technology supporting next-generation digital assets, including Real Bank Deposit Tokens (RBDTs). The majority of revenue comes from Digital Banking.